NCT00025259 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 52
- group Id
- BG001
- value
- 381
- group Id
- BG002
- value
- 382
- group Id
- BG003
- value
- 571
- group Id
- BG004
- value
- 42
- group Id
- BG005
- value
- 153
- group Id
- BG006
- value
- 153
- group Id
- BG007
- value
- 1734
- units
- Participants
- groups
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG000
- title
- Arm I (Patients Off-therapy Before Callback-Induction Only)
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Involved-Field Radiation Therapy: Undergo IFRT Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG001
- title
- Arm II (RER With CR [ABVE-PC, IFRT])
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG002
- title
- Arm III (RER With CR [ABVE-PC])
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Involved-Field Radiation Therapy: Undergo IFRT Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG003
- title
- Arm IV (RER With Less Than CR [ABVE-PC, IFRT])
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG004
- title
- Arm V (RER With PD)
- description
- Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, \& cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 \& 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 \& G-CSF SC beginning on day 3 \& continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy. Bleomycin Sulfate: Given IV or SC Cisplatin: Given IV Cyclophosphamide: Given IV Cytarabine: Given IV Dexamethasone: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Involved-Field Radiation Therapy: Undergo IFRT Pre
- id
- BG005
- title
- Arm VI (SER [DECA, ABVE-PC, IFRT])
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Involved-Field Radiation Therapy: Undergo IFRT Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG006
- title
- Arm VII (SER [ABVE-PC, IFRT])
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 363
- group Id
- BG002
- value
- 369
- group Id
- BG003
- value
- 540
- group Id
- BG004
- value
- 40
- group Id
- BG005
- value
- 143
- group Id
- BG006
- value
- 148
- group Id
- BG007
- value
- 1649
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 31
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 85
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 5
- upper Limit
- 20
- value
- 16
- group Id
- BG001
- lower Limit
- 2
- upper Limit
- 21
- value
- 14
- group Id
- BG002
- lower Limit
- 3
- upper Limit
- 21
- value
- 14
- group Id
- BG003
- lower Limit
- 1
- upper Limit
- 21
- value
- 15
- group Id
- BG004
- lower Limit
- 5
- upper Limit
- 19
- value
- 15
- group Id
- BG005
- lower Limit
- 5
- upper Limit
- 21
- value
- 15
- group Id
- BG006
- lower Limit
- 5
- upper Limit
- 21
- value
- 15
- group Id
- BG007
- lower Limit
- 1
- upper Limit
- 21
- value
- 15
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 177
- group Id
- BG002
- value
- 155
- group Id
- BG003
- value
- 288
- group Id
- BG004
- value
- 16
- group Id
- BG005
- value
- 81
- group Id
- BG006
- value
- 77
- group Id
- BG007
- value
- 815
- title
- Female
- measurements
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 204
- group Id
- BG002
- value
- 227
- group Id
- BG003
- value
- 283
- group Id
- BG004
- value
- 26
- group Id
- BG005
- value
- 72
- group Id
- BG006
- value
- 76
- group Id
- BG007
- value
- 919
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 71
- group Id
- BG002
- value
- 67
- group Id
- BG003
- value
- 74
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 22
- group Id
- BG006
- value
- 14
- group Id
- BG007
- value
- 259
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 44
- group Id
- BG001
- value
- 293
- group Id
- BG002
- value
- 306
- group Id
- BG003
- value
- 487
- group Id
- BG004
- value
- 34
- group Id
- BG005
- value
- 127
- group Id
- BG006
- value
- 134
- group Id
- BG007
- value
- 1425
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 50
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 4
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 50
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 6
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 45
- group Id
- BG002
- value
- 43
- group Id
- BG003
- value
- 67
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 14
- group Id
- BG006
- value
- 14
- group Id
- BG007
- value
- 194
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 290
- group Id
- BG002
- value
- 297
- group Id
- BG003
- value
- 444
- group Id
- BG004
- value
- 30
- group Id
- BG005
- value
- 122
- group Id
- BG006
- value
- 124
- group Id
- BG007
- value
- 1348
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 27
- group Id
- BG003
- value
- 45
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 12
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 132
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 4
- title
- New Zealand
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 45
- group Id
- BG003
- value
- 51
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 20
- group Id
- BG006
- value
- 20
- group Id
- BG007
- value
- 175
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 333
- group Id
- BG002
- value
- 312
- group Id
- BG003
- value
- 491
- group Id
- BG004
- value
- 39
- group Id
- BG005
- value
- 125
- group Id
- BG006
- value
- 128
- group Id
- BG007
- value
- 1469
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 6
- title
- Israel
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 12
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 40
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Switzerland
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Kuwait
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 22
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 13
- title
- Puerto Rico
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Bermuda
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- French Polynesia
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 52
- group Id
- BG001
- value
- 381
- group Id
- BG002
- value
- 382
- group Id
- BG003
- value
- 571
- group Id
- BG004
- value
- 42
- group Id
- BG005
- value
- 153
- group Id
- BG006
- value
- 153
- group Id
- BG007
- value
- 1734
- units
- Participants
- groups
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin sulfate IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, oral prednisone 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG000
- title
- Arm I (Patients Off-therapy Before Callback-Induction Only)
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR undergo IFRT approximately 3 weeks after the last day of ABVE course 4. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Involved-Field Radiation Therapy: Undergo IFRT Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG001
- title
- Arm II (RER With CR [ABVE-PC, IFRT])
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with sustained CR are randomized to receive no further treatment. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG002
- title
- Arm III (RER With CR [ABVE-PC])
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive an additional 2 courses of ABVE-PC. Patients with VGPR, PR or SD undergo IFRT approximately 3 weeks after the last day of ABVE-PC course 4 for 5 days a week. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Involved-Field Radiation Therapy: Undergo IFRT Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG003
- title
- Arm IV (RER With Less Than CR [ABVE-PC, IFRT])
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients with PD are taken off therapy. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG004
- title
- Arm V (RER With PD)
- description
- Patients receive dexamethasone IV over 15 minutes, etoposide IV over 3 hours, \& cytarabine IV over 3 hours on days 1-2. Patients receive 2 drops of dexamethasone ophthalmic solution every 6 hours on days 1, 2 \& 3. Patients also receive cisplatin PO or IV over 12 hours as pre-hydration followed by continuous IV over 6 hours on day 1 \& G-CSF SC beginning on day 3 \& continuing until blood counts recover. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity. Patients then receive 2 additional courses of ABVE-PC chemotherapy. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy. Bleomycin Sulfate: Given IV or SC Cisplatin: Given IV Cyclophosphamide: Given IV Cytarabine: Given IV Dexamethasone: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Involved-Field Radiation Therapy: Undergo IFRT Pre
- id
- BG005
- title
- Arm VI (SER [DECA, ABVE-PC, IFRT])
- description
- Patients receive doxorubicin IV over 10-30 minutes on days 1-2, bleomycin IV over 10-20 minutes or SC and vincristine IV on days 1 and 8, etoposide IV over 1 hour on days 1-3, prednisone PO 2 or 3 times daily on days 1-7, and cyclophosphamide IV over 1 hour on day 1. Patients receive filgrastim (G-CSF) SC beginning on day 2 and continuing until blood counts recover (G-CSF is held on day 8). Treatment repeats every 21 days for 2 courses in the absence of progressive disease. Patients receive 2 additional courses of ABVE-PC. Patients with sustained complete or partial response undergo IFRT approximately 3 weeks after the last course of chemotherapy. Bleomycin Sulfate: Given IV or SC Cyclophosphamide: Given IV Doxorubicin Hydrochloride: Given IV Etoposide: Given IV Filgrastim: Given SC Involved-Field Radiation Therapy: Undergo IFRT Prednisone: Given orally Vincristine Sulfate Liposome: Given IV
- id
- BG006
- title
- Arm VII (SER [ABVE-PC, IFRT])
- description
- Total of all reporting groups
- id
- BG007
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 46
- group Id
- BG001
- value
- 363
- group Id
- BG002
- value
- 369
- group Id
- BG003
- value
- 540
- group Id
- BG004
- value
- 40
- group Id
- BG005
- value
- 143
- group Id
- BG006
- value
- 148
- group Id
- BG007
- value
- 1649
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 18
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 31
- group Id
- BG004
- value
- 2
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 85
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 5
- upper Limit
- 20
- value
- 16
- group Id
- BG001
- lower Limit
- 2
- upper Limit
- 21
- value
- 14
- group Id
- BG002
- lower Limit
- 3
- upper Limit
- 21
- value
- 14
- group Id
- BG003
- lower Limit
- 1
- upper Limit
- 21
- value
- 15
- group Id
- BG004
- lower Limit
- 5
- upper Limit
- 19
- value
- 15
- group Id
- BG005
- lower Limit
- 5
- upper Limit
- 21
- value
- 15
- group Id
- BG006
- lower Limit
- 5
- upper Limit
- 21
- value
- 15
- group Id
- BG007
- lower Limit
- 1
- upper Limit
- 21
- value
- 15
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- Years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 21
- group Id
- BG001
- value
- 177
- group Id
- BG002
- value
- 155
- group Id
- BG003
- value
- 288
- group Id
- BG004
- value
- 16
- group Id
- BG005
- value
- 81
- group Id
- BG006
- value
- 77
- group Id
- BG007
- value
- 815
- title
- Female
- measurements
- group Id
- BG000
- value
- 31
- group Id
- BG001
- value
- 204
- group Id
- BG002
- value
- 227
- group Id
- BG003
- value
- 283
- group Id
- BG004
- value
- 26
- group Id
- BG005
- value
- 72
- group Id
- BG006
- value
- 76
- group Id
- BG007
- value
- 919
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 71
- group Id
- BG002
- value
- 67
- group Id
- BG003
- value
- 74
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 22
- group Id
- BG006
- value
- 14
- group Id
- BG007
- value
- 259
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 44
- group Id
- BG001
- value
- 293
- group Id
- BG002
- value
- 306
- group Id
- BG003
- value
- 487
- group Id
- BG004
- value
- 34
- group Id
- BG005
- value
- 127
- group Id
- BG006
- value
- 134
- group Id
- BG007
- value
- 1425
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 17
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 10
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 5
- group Id
- BG007
- value
- 50
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 4
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 15
- group Id
- BG002
- value
- 12
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 4
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 50
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 6
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 45
- group Id
- BG002
- value
- 43
- group Id
- BG003
- value
- 67
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 14
- group Id
- BG006
- value
- 14
- group Id
- BG007
- value
- 194
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 290
- group Id
- BG002
- value
- 297
- group Id
- BG003
- value
- 444
- group Id
- BG004
- value
- 30
- group Id
- BG005
- value
- 122
- group Id
- BG006
- value
- 124
- group Id
- BG007
- value
- 1348
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 27
- group Id
- BG003
- value
- 45
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 12
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 132
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 4
- title
- New Zealand
- categories
- measurements
- group Id
- BG000
- value
- 8
- group Id
- BG001
- value
- 30
- group Id
- BG002
- value
- 45
- group Id
- BG003
- value
- 51
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 20
- group Id
- BG006
- value
- 20
- group Id
- BG007
- value
- 175
- title
- Canada
- categories
- measurements
- group Id
- BG000
- value
- 41
- group Id
- BG001
- value
- 333
- group Id
- BG002
- value
- 312
- group Id
- BG003
- value
- 491
- group Id
- BG004
- value
- 39
- group Id
- BG005
- value
- 125
- group Id
- BG006
- value
- 128
- group Id
- BG007
- value
- 1469
- title
- United States
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 6
- title
- Israel
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 13
- group Id
- BG003
- value
- 12
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 4
- group Id
- BG007
- value
- 40
- title
- Australia
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Switzerland
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Kuwait
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- France
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 3
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 22
- title
- Netherlands
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 4
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 13
- title
- Puerto Rico
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- Bermuda
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- title
- French Polynesia
- param Type
- NUMBER
- title
- Region of Enrollment
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle